Cytokinetics Announces Presentation of Preclinical Data Regarding CK-2017357 … – MarketWatch (press release)


Xconomy
Cytokinetics Announces Presentation of Preclinical Data Regarding CK-2017357
MarketWatch (press release)
In addition, CK-2017357 has received Fast Track designation from the US Food and Drug Administration for the potential treatment of ALS. Cytokinetics recently completed a two-part, Phase II safety, tolerability, pharmacokinetic and pharmacodynamic
Cytokinetics Announces Encouraging Results From Two Phase II Clinical Trials Marketwire (press release)

all 13 news articles »

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>